Impact Biomedical INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
AMEX
Impact BioMedical Inc. announces a planned reverse stock split with a ratio between 1-for-12.48 and 1-for-50, approved by majority stockholders to enhance market perception and meet listing requirements.
AMEX
Impact BioMedical Inc. announces its 2025 Annual Meeting of Stockholders to elect directors, ratify auditors, and hold an advisory vote on executive compensation.
AMEX
Impact BioMedical Inc. will issue 31.9 million common shares to DSS, Inc. to convert a $12 million debt, making DSS the majority common shareholder.
AMEX
Impact BioMedical Inc. announces the approval of its 2023 Equity Incentive Plan, reserving up to 5 million common shares for employee and director compensation.